Important information regarding cookies and
By using this website, you consent to the use of cookies in accordance with the IMB Cookie Policy. For more information on cookies, see our Cookie Policy.
Full Version | Search

The Irish Medicines Board -

IMB Logo

Onglyza (saxagliptin) - Important Safety Information from Bristol-Myers Squibb as approved by the Irish Medicines Board

12 March 2012

Important Safety Information communication from Bristol-Myers Squibb on the association of Onglyza (saxagliptin) with serious hypersensitivity reactions and acute pancreatitis.

Important Safety Information - Onglyza

Date Printed: 19 April 2014

© Irish Medicines Board 2014 | Developed by Engine Solutions

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971